Through an exchange filing, Revital maker Sun Pharma has informed that it has received a warning letter from the US Food and Drug Administration.
The letter specifies violations at its Halol facility, with regards to manufacturing of goods, and contents of the letter will be released to the public soon.
(To receive our E-paper on WhatsApp daily, please click here. To receive it on Telegram, please click here. We permit sharing of the paper's PDF on WhatsApp and other social media platforms.)
